Trials / Unknown
UnknownNCT01436214
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Adamis Pharmaceuticals Corporation · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase 1/2a, open label, dose escalation and safety study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APC-100 | Daily oral, dose escalation, 28-day cycle(s) |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2016-08-01
- Completion
- 2017-08-01
- First posted
- 2011-09-19
- Last updated
- 2015-07-16
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01436214. Inclusion in this directory is not an endorsement.